Pfizer (PFE) Liabilities and Shareholders Equity (2016 - 2025)
Pfizer (PFE) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $208.2 billion as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 2.45% to $208.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $831.0 billion through Dec 2025, down 4.5% year-over-year, with the annual reading at $208.2 billion for FY2025, 2.45% down from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $208.2 billion at Pfizer, roughly flat from $208.7 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $226.5 billion in Q4 2023, with the low at $41.1 billion in Q4 2022.
- Average Liabilities and Shareholders Equity over 5 years is $186.6 billion, with a median of $207.0 billion recorded in 2025.
- The sharpest move saw Liabilities and Shareholders Equity dropped 11.22% in 2022, then soared 422.64% in 2023.
- Over 5 years, Liabilities and Shareholders Equity stood at $181.5 billion in 2021, then grew by 8.67% to $197.2 billion in 2022, then increased by 14.86% to $226.5 billion in 2023, then dropped by 5.79% to $213.4 billion in 2024, then fell by 2.45% to $208.2 billion in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $208.2 billion, $208.7 billion, and $206.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.